Tetanus Toxoid Adsorbed
"The Centers for Disease Control and Prevention (CDC), in partnership with the Sierra Leone College of Medicine and Allied Health Sciences (COMAHS) and the Sierra Leone Ministry of Health and Sanitation (MoHS), is now enrolling and vaccinating vol"...
Tetanus Toxoid Adsorbed
This product contains dry natural latex rubber as follows: The stopper to the vial contains dry natural latex rubber.
Persons who experienced Arthus-type hypersensitivity reactions or a temperature of > 103°F ( > 39.4°C) following a prior dose of tetanus toxoid usually have high serum tetanus antitoxin levels and should not be given even emergency doses of Tetanus Toxoid Adsorbed more frequently than every 10 years, even if they have a wound that is neither clean nor minor.1
A routine booster should not be given more frequently than every ten years. (This guideline should not preclude wound management considerations.)
Care is to be taken by the health-care provider for the safe and effective use of Tetanus Toxoid Adsorbed vaccine.
EPINEPHRINE INJECTION (1:1000) MUST BE IMMEDIATELY AVAILABLE SHOULD AN ACUTE ANAPHYLACTIC REACTION OCCUR DUE TO ANY COMPONENT OF THE VACCINE.
There is an increased incidence of local and systemic reactions to booster doses of tetanus toxoid when given to previously immunized persons. (Refer to DOSAGE AND ADMINISTRATION section for timing of booster injections.) Prior to an injection of any vaccine, all known precautions should be taken to prevent adverse reactions. This should include a review of the patient's history with respect to possible sensitivity and any previous adverse reactions (see CONTRAINDICATIONS section) to the vaccine or similar vaccines and to possible sensitivity to dry natural latex rubber, and a current knowledge of the literature concerning the use of the vaccine under consideration.
Special care should be taken to ensure that the injection does not enter a blood vessel.
Immunosuppressive therapies including radiation, corticosteroids, antimetabolites, alkylating agents, and cytotoxic drugs may reduce the immune response to vaccines. Therefore, routine vaccination should be deferred, if possible, while patients are receiving such therapy.1 If Tetanus Toxoid Adsorbed vaccine has been administered to persons receiving immunosuppressive therapy, or having an immunodeficiency disorder, an adequate antibody response may not be obtained.1 When possible, immunosuppressive treatment should be interrupted when immunization is required due to a tetanus-prone wound.
It is advisable to use DT (For Pediatric Use – under 7 years of age) or Td (For Adult Use – 7 years of age and older) in wound prophylaxis instead of tetanus toxoid alone in order to maintain adequate levels of diphtheria immunity.1
A separate, sterile syringe and needle or a sterile disposable unit must be used for each patient to prevent transmission of hepatitis or other infectious agents from person to person. Needles should not be recapped and should be disposed of according to biohazard waste guidelines.
Carcinogenesis, Mutagenesis, Impairment of Fertility
No studies have been performed to evaluate carcinogenicity, mutagenic potential, or impact on fertility.
Reproductive Studies – Pregnancy Category C
Animal reproduction studies have not been conducted with Tetanus Toxoid Adsorbed vaccine. It is also not known whether Tetanus Toxoid Adsorbed vaccine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Tetanus Toxoid Adsorbed vaccine should be given to a pregnant woman only if clearly needed.
Adequate immunization by routine boosters in non-pregnant women of child-bearing age can obviate the need to vaccinate women during pregnancy (see DOSAGE AND ADMINISTRATION section).
Physicians generally avoid prescribing unnecessary drugs and biologics for pregnant women.
However, the ACIP recommends the following: A previously unvaccinated pregnant woman whose child might be born under unhygienic circumstances (without sterile technique) should receive two doses of Td 4 to 8 weeks apart before delivery, preferably during the last two trimesters. Pregnant women in similar circumstances who have not had a complete vaccination series should complete the three-dose series. Those vaccinated more than 10 years previously should have a booster dose. No evidence exists to indicate that tetanus and diphtheria toxoids administered during pregnancy are teratogenic.1
It has been reported that tetanus toxoid administered to pregnant women prevents neonatal tetanus in newborns.11,12 However, the data reported on the safety of tetanus toxoid when so used is inconclusive because the incidence of neonatal deaths in New Guinea was significantly higher than in the United States.11 A prospective study in the United States has not been done to confirm these reports.
SAFETY AND EFFECTIVENESS OF TETANUS TOXOID ADSORBED VACCINE IN INFANTS BELOW THE AGE OF SIX WEEKS HAVE NOT BEEN ESTABLISHED. HOWEVER, THIS VACCINE IS NOT INDICATED FOR CHILDREN UNDER 7 YEARS OF AGE.
Tetanus Toxoid Adsorbed vaccine is suitable for tetanus immunization in the pediatric age group. However, for children under 7 years of age DT (For Pediatric Use) is preferred to tetanus toxoid alone if the pertussis component is contraindicated. For children 7 years of age and older, Td (For Adult Use) is preferred to tetanus toxoid alone.1
1. Recommendations of the Immunization Practices Advisory Committee (ACIP). Diphtheria, Tetanus, and Pertussis: Recommendations for vaccine use and other preventive measures. MMWR 40: No. RR-10, 1991
6. Stratton KR, et al. Adverse events associated with childhood vaccines. Evidence Bearing on Causality. National Academy Press, Washington, DC, 1994
7. ACIP. General recommendations on immunization. MMWR 38: 205-227, 1989
11. MacLennan R, et al. Immunization against neonatal tetanus in New Guinea. Antitoxin response of pregnant women to adjuvant and plain toxoids. Bull WHO 32: 683-697, 1965
12. Newell KW, et al. The use of toxoid for the prevention of tetanus neonatorium. Bull WHO 35: 863-871, 1966This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 1/13/2009
Additional Tetanus Toxoid Adsorbed Information
Tetanus Toxoid Adsorbed - User Reviews
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.